118 HR 4053 IH: Studying Suboxone Act U.S. House of Representatives 2023-06-13 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I 118th CONGRESS1st Session H. R. 4053 IN THE HOUSE OF REPRESENTATIVES June 13, 2023 Ms. Kuster (for herself and Mr. Carter of Georgia) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.

1.

Short title

This Act may be cited as the Studying Suboxone Act.

2.

Reviewing the scheduling of buprenorphine-naloxone combination products

(a)

Secretary of HHS

The Secretary of Health and Human Services shall— (1)review and, as appropriate, update the scientific and medical evaluation conducted under section 201(b) of the Controlled Substance Act (21 U.S.C. 811(b)) with respect to buprenorphine-naloxone combination products; and (2)update, as necessary, the Secretary’s scheduling recommendation under such section with respect to such products. (b)

Attorney General

The Attorney General shall— (1)review the recommendations provided by the Secretary under subsection (a), and all other relevant data with respect to the scheduling of buprenorphine-naloxone combination products; (2)consider the factors listed in subsection (c) of section 201 of the Controlled Substance Act (21 U.S.C. 811) with respect to such products; and (3)consistent with such section 201, make such scheduling changes with respect to such products as the Secretary may determine appropriate.